Clinical trial
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic…
NCT00434954 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00434954 |
|---|---|
| Title | Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes |
| Official title | Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | exenatide twice daily (BID), premixed insulin aspart twice daily (BID) |
| Enrollment | 494 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Feb 14, 2007 |
| Last update posted | Apr 7, 2015 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: